TG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 Transcript

TG Therapeutics' CEO Michael Weiss reported BRIUMVI continues to exceed sales expectations since its February 2023 launch, driven by its differentiated profile and competitive pricing, and is now expanding into direct-to-patient marketing to sustain growth. The company reaffirmed its conservative 2025 revenue guidance of $570M-$575M and announced a new $100 million share buyback authorization. Strategically, TG Therapeutics anticipates its forthcoming subcutaneous BRIUMVI formulation will significantly expand market opportunity, and views the eventual OCREVUS biosimilar entry as an opportunity rather than a threat, reinforcing confidence in BRIUMVI's long-term market position.

Analysis

TG Therapeutics is demonstrating strong commercial execution with its multiple sclerosis drug, BRIUMVI, which has consistently exceeded sales expectations since its February 2023 launch. The company's CEO attributes this success to a multi-faceted value proposition: best-in-class efficacy data showing an annualized relapse rate below 0.1, a superior tolerability and convenience profile with a one-hour infusion, and a significant 25% price discount to its main competitor. Having established a strong prescriber base, the company is now initiating a direct-to-patient marketing campaign, including TV advertising, which it considers a significant future growth tailwind. Management reaffirmed its conservative 2025 revenue guidance of $570M-$575M, defending its philosophy of setting high-confidence targets. Strategically, TG Therapeutics sees the eventual launch of an OCREVUS biosimilar as an opportunity rather than a threat, arguing BRIUMVI's existing discount and differentiation will insulate it. The pipeline's key catalyst is a subcutaneous version of BRIUMVI, designed as a low-volume auto-injector, which could nearly double the addressable market. This confidence is further underscored by a new $100 million share buyback authorization, with management explicitly stating its intention to purchase shares aggressively on any price weakness.

Key Decisions for Investors

• Investors should monitor BRIUMVI's market share trajectory, as the new direct-to-patient marketing initiative is positioned as the next key catalyst for accelerating growth beyond its current capture of one-third of new IV CD20 patient starts.
• Given the CEO's explicit 'conservative' guidance philosophy, the reaffirmed $570M-$575M revenue guidance should be viewed as a high-confidence floor, with potential for continued modest upside in quarterly results.
• The development of the subcutaneous BRIUMVI formulation represents a primary long-term catalyst that could significantly expand the franchise's value by nearly doubling the addressable market and offering a more convenient profile than competing subcutaneous options.
• The new $100 million share repurchase authorization, coupled with management's commentary on buying aggressively during dips, signals strong conviction that the stock is undervalued relative to its predictable and growing cash flow potential.
• Evaluate the long-term competitive landscape by considering management's contrarian thesis that an OCREVUS biosimilar could be a net positive for BRIUMVI, potentially allowing it to gain share from the branded competitor without significant price erosion.